BioCryst Pharmaceuticals, Inc. (BCRX) Stock

About BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. (BCRX) stock trades at $7.65 with a market capitalization of $1.95B. The stock is valued at a negative price-to-earnings (P/E) ratio of -5.60, reflecting a net loss over the last twelve months, a negative price-to-book of -4.51, reflecting negative shareholders' equity, price-to-sales of 2.19. Over the past 52 weeks the stock has ranged between $6.23 and $11.22, and currently trades 31.8% below its 52-week high.

On profitability, BioCryst Pharmaceuticals, Inc. generates a return on equity (ROE) of 101.55% (not meaningful, as shareholders' equity is negative), return on capital employed of -89.73%, an operating margin of 38.97%, a net profit margin of -40.90%.

BioCryst Pharmaceuticals, Inc. by the numbers, 2016–2025

Between 2016 and 2025 BioCryst Pharmaceuticals, Inc. reported revenue of $26.0M rising to $875.0M, a change of +3265.4% across 10 years. Compounded, revenue has grown 117.4% a year over five years, 47.8% over three, 94.0% over the last twelve months. Net profit rose to $264.0M.

Operating margin went from -184.4% in 2016 to 39.0% in 2025, a gain of 223.4 percentage points. The most recent net margin is -40.90%. On a trailing twelve-month basis to Jun '26, revenue is $940.0M and net profit $-385.0M.

Borrowings rose from $54.0M to $439.0M, cash from operations was $330.0M in the latest year, positive in 1 of the last 10.

Return on equity has averaged 20.5% over five years, and was -221.8% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

BioCryst Pharmaceuticals, Inc. (BCRX) — frequently asked questions